Med24
overweight-obesity 8. 10. 2026 • 2 min read • Clinical and experimental reproductive medicine

Beyond body mass index: A contemporary review of obesity and female infertility

Obesity is increasingly understood as a reproductive-metabolic condition that can affect female fertility across the continuum from natural conception to assisted reproductive technology (ART). Excess adiposity may disrupt hypothalamic-pituitary-ovarian regulation, insulin signaling, inflammatory pathways, ovarian...

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

Obesity is recognized as a condition impacting female fertility throughout the process of conception, including natural and assisted reproductive technologies. Excess body fat can interfere with the regulation of the hypothalamus, pituitary gland, and ovaries. It also affects insulin signaling, inflammatory processes, oocyte quality, embryo development, and the receptivity of the uterine lining.

Sponsored content

Key Clinical Findings

The review examines the connections between obesity and infertility, decreased effectiveness of ART, implantation difficulties, miscarriage, and lower live birth rates. These relationships are influenced by individual reproductive and metabolic characteristics. Specific conditions such as polycystic ovary syndrome, advanced age, reduced ovarian reserves, recurrent implantation failure, and recurrent pregnancy loss are highlighted in the context of obesity’s impact. The review considers strategies for weight reduction before fertility treatment, including lifestyle changes, glucagon-like peptide-1 receptor agonists, tirzepatide, and bariatric surgery. These approaches are evaluated for their potential to improve reproductive outcomes, the possible delay in treatment, and considerations for safety during pregnancy.

Original Scientific Source
Clinical and experimental reproductive medicine
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study
overweight-obesity

Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study

Summary Background Hand and shoulder soft-tissue disorders cluster in people with obesity and diabetes, now widely treated with incretin receptor agonists. Whether these disorders share genetic causes, and whether pharmacological weight loss relieves or provokes them, is unknown. Methods We analysed genome-wide data...

28. 10. 2026 Read article →
The interpretation of body-composition metrics in obesity
overweight-obesity

The interpretation of body-composition metrics in obesity

Modern obesity care is increasingly therapeutic, longitudinal, and outcome-oriented, yet clinical assessment often remains centered on total body weight and BMI. Although BMI remains useful for screening and population-level risk stratification, it cannot characterize the biological heterogeneity of obesity or the...

26. 10. 2026 Read article →
Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial
overweight-obesity

Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial

Background Orforglipron, an oral small-molecule glucagon-like peptide-1 receptor agonist, improved body weight and cardiometabolic parameters in the phase 3 ATTAIN-1 trial, but its efficacy and safety in adults with body mass index (BMI) of ≥27 to 2 and adiposity-related complications have not been characterized....

14. 10. 2026 Read article →
Advertisement